A real-world study to assess Sacubitril/valsartan in heart failure with reduced ejection fraction patients in India
Not Applicable
- Conditions
- Health Condition 1: I501- Left ventricular failure, unspecified
- Registration Number
- CTRI/2021/01/030802
- Lead Sponsor
- ovartis Healthcare Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients >= 18 years with a diagnosis of HFrEF as mentioned in database or heart failure with a recording of LVEF <40% at or before the index date.
A prescription of sacubitril/valsartan
Exclusion Criteria
Diagnosis of HF specified as preserved/mid-range ejection fraction
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Sacubitril/valsartan's efficacy in HFrEF patients with left ventricular failure?
How does real-world use of Sacubitril/valsartan compare to standard-of-care ARBs in reducing HFrEF hospitalizations in India?
Which biomarkers correlate with improved outcomes in HFrEF patients treated with ARNIs like Sacubitril/valsartan?
What adverse events are associated with Sacubitril/valsartan in observational HFrEF trials, and how are they managed?
Are there alternative neprilysin inhibitor-based therapies or combination strategies for HFrEF under Novartis investigation?